Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Autifony Announces Collaboration with Universities of Manchester and Newcastle

Published: Monday, July 01, 2013
Last Updated: Monday, July 01, 2013
Bookmark and Share
£2.75 million research collaboration to progress a first-in-class drug for schizophrenia.

Autifony Therapeutics Limited has announced a collaboration with research groups at the University of Manchester and Newcastle University to develop a novel, first-in-class Kv3 potassium channel modulator for the treatment of schizophrenia.

The £2.75 million research collaboration is part-funded by the award of a £1.9 million grant to Autifony and the two Universities, by the UK’s innovation agency, the Technology Strategy Board.

The award follows a successful funding application to the Biomedical Catalyst, jointly funded by the Technology Strategy Board and the Medical Research Council.

Autifony’s lead programme is developing first-in-class Kv3 potassium channel modulators for hearing loss and tinnitus. This new collaboration aims to develop pharmaceutical compounds against the same target but with profiles differentiated and distinct from its hearing programme.

Autifony and its collaborators will explore the modulation of this novel voltage gated potassium channel mechanism as a potential new therapy for schizophrenia.

A serious psychiatric illness that has seen diminishing investment in research in recent years, schizophrenia remains an area of high unmet medical need, with existing schizophrenia treatments demonstrating poor efficacy for many patients as well as causing considerable side effects.

The condition imposes a huge social and economic burden.

The funding award will be used to enable selection of a compound from a group of potential candidates and then progression of the chosen compound through preclinical development up to a CTA/IND submission.

Autifony is working closely with leading academic collaborators, Professors Neill, Williams and Deakin at the University of Manchester, and Drs Cunningham and LeBeau at Newcastle University, whose pioneering models of schizophrenia will give further validation of the target and insight into the disease pathology.

Dr Charles Large, Chief Scientific Officer of Autifony, commented: “The opportunity provided by this grant to work on a new approach to schizophrenia, for which novel and more effective treatments are urgently needed, is hugely exciting. The ion channels that we are targeting in our hearing loss programme are closely implicated in brain circuits which are believed to be dysfunctional in schizophrenia. Working with academic collaborators renowned in their respective fields will bring the latest techniques and thinking to bear on this important health challenge.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
13 Ways to Stop an Unseen Force from Disrupting Weighing
Download a free Mettler Toledo paper to discover how to halt static’s negative effects before the next weigh-in.
Inroads Against Leukemia
Potential for halting disease in molecule isolated from sea sponges.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.
Researchers Discover A New Mechanism of Proteins to Block HIV
Certain IFITM proteins block and inhibit cell-to-cell transmission of HIV.
Opening the Door to Safer, More Precise Cancer Therapies
New method regulates when, and how strongly, cancer-killing therapeutic T cells are activated.
Vaccination On The Horizon For Severe Viral Infection Of The Brain
Researchers from the University of Zurich and the University Hospital Zurich reveal possible new treatment methods for a rare, usually fatal brain disease.
‘Immune Camouflage’ may Explain H7N9 Influenza Vaccine Failure
The study is published in Human Vaccines & Immunotherapeutics.
Revolutionary Gene-editing Technique to Stop AIDS Virus in Its Tracks
UNLV personalized medicine researchers seeking patent on potential HIV cure. Their technique uses a plant protein widely used in agriculture industry.
Drug Disarms Deadly C. difficile Bacteria Without Destroying Healthy Gut Flora
A drug that blocks the intestinal pathogen without killing resident, beneficial microbes may prove superior to antibiotics, currently the front-line treatment for the infection.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos